| Literature DB >> 32823530 |
Jarosław Nuszkiewicz1, Alina Woźniak1, Karolina Szewczyk-Golec1.
Abstract
Ionizing radiation (IR) has found widespread application in modern medicine, including medical imaging and radiotherapy. As a result, both patients and healthcare professionals are exposed to various IR doses. To minimize the negative side effects of radiation associated with oxidative imbalance, antioxidant therapy has been considered. In this review, studies on the effects of melatonin and vitamin D on radiation-induced oxidative stress are discussed. According to the research data, both substances meet the conditions for use as agents that protect humans against IR-induced tissue damage. Numerous studies have confirmed that melatonin, a hydro- and lipophilic hormone with strong antioxidant properties, can potentially be used as a radioprotectant in humans. Less is known about the radioprotective effects of vitamin D, but the results to date have been promising. Deficiencies in melatonin and vitamin D are common in modern societies and may contribute to the severity of adverse side effects of medical IR exposure. Hence, supporting supplementation with both substances seems to be of first importance. Interestingly, both melatonin and vitamin D have been found to selectively radiosensitise cancer cells, which makes them promising adjuvants in radiotherapy. More research is needed in this area, especially in humans.Entities:
Keywords: ionizing radiation; melatonin; oxidative stress; radioprotection; reactive oxygen species; vitamin D
Mesh:
Substances:
Year: 2020 PMID: 32823530 PMCID: PMC7460937 DOI: 10.3390/ijms21165804
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Melatonin and its metabolites as antioxidants. Abbreviations used: 3-OHM—3-hydroxymelatonin, AFMK—N1-acetyl-N2-formyl-5-methoxykynuramine, AMK—N1-acetyl-5-methoxykynuramine, GPx—glutathione peroxidase, GR—glutathione reductase, GSH—glutathione, GSSG—glutathione disulphide, NO—nitric oxide, RNS—reactive nitrogen species, ROS—reactive oxygen species, SOD—superoxide dismutase.
Research on the impact of ionizing radiation on the generation of reactive oxygen species and the radioprotective role of melatonin.
| Subjects | Melatonin Dosage (Route of Administration) | Time of Melatonin Administration | Radiation Dosage (Irradiation Area) | Outcomes | Reference |
|---|---|---|---|---|---|
| Adult male Sprague-Dawley rats | 10 and 20 mg/kg (IP injection) | Immediately before and after irradiation | X-ray radiation of 8 Gy | Melatonin reduced the levels of MDA and increased the GSH concentration. | [ |
| Adult female Sprague-Dawley rats | 30 and 5 mg/kg (IP injection) | 30 min prior to irradiation and on the following days of experiment | Gamma radiation of 5 and 8 Gy (total cranial) | Melatonin decreased the formation of late side effects of radiation. Melatonin administration during radiotherapy protected ocular lenses against radiation-induced oxidative injuries. | [ |
| Adult male Wistar rats | 100 and 5 mg/kg (IP injection) | 30 min before irradiation and once a day per after irradiation | Gamma radiation 22 Gy (cervical segment of the spinal cord) | Melatonin increased survival rate and decreased histopathological changes. | [ |
| Adult male Wistar rats | 50 mg/kg (IP injection) | 15 min prior to irradiation | 18 Gy (anatomical area of the heart position) | Melatonin prevented the development of vasculitis, reduced myocyte necrosis and cardiac fibrosis. | [ |
| Adult male Wistar rats | 10, 20, and 10 mg/kg (IP injection) | Before irradiation, just after irradiation and 24h after irradiation | Gamma radiation 8 Gy, twice (whole body and abdominopelvic) | Melatonin administration inhibited primary spermatocyte degeneration. | [ |
| Adult male Wistar rats | 0.2 mg/day (IP injection) | Once a day for 14 days before irradiation | Gamma radiation 8 Gy (whole body) | Melatonin had a protective effect on suprarenal gland. | [ |
| Adult male Wistar rats | 5 and 10 mg/kg (IP injection) | 30 min before irradiation | Gamma radiation 6 Gy (whole body) | Melatonin decreased hepatic MDA and nitric oxide (NO) levels. | [ |
| Adult male Wistar rats | 45 mg/day (PO) | Once a day for 21 days before irradiation | X-ray 7.5 Gy/day for five consecutive days (oral cavity) | Melatonin increased the activities and protein levels of GPx, GR, SOD2 and strongly decreased inflammasome activation. | [ |
| Adult both sexes Wistar rats | 100 mg/kg (IP injection) | For 5 days post radiation | Total dose of 7.2 Gy in two fractions (whole body) | Melatonin reduced MDA level, rates of oedema, necrosis, neuronal degeneration, and vasodilatation. | [ |
| Adult male mice | From 0.9–1.0 to 1.2 mg/kg (PO) | From the third day after irradiation | Gamma radiation 9.5–10 Gy (whole body) | Melatonin reduced symptoms of acute radiation sickness, increased survival rate and leukocyte level. | [ |
| Adult male Swiss albino mice | 0.1 mg/kg/day (PO) | 15 consecutive days prior to radiation | Gamma radiation 6, 8 and 10 Gy (whole body) | Melatonin reduced lipid peroxidation, glutathione disulphide (GSSG) level, deficit in the body and organ weight. Melatonin increased GSH level and survival rate. | [ |
| Young adult male squirrels | 250 mg/kg (SC injection) | Once a day for four weeks before irradiation | X-ray radiation of 2.06 Gy (abdominal, near the splenic region) | Long term melatonin treatment protected the splenocytes and modulated endogenous DNA repair activity. | [ |
| In vitro, human blood | 300 mg (PO) | 1 h before irradiation of blood sample | Gamma radiation 1 Gy (blood sample) | Melatonin reduced primary DNA damage. | [ |
Abbreviations used: IP injection—intraperitoneal injection, PO—oral administration, SC injection—subcutaneous injection.
Figure 2Antioxidant properties of vitamin D. Abbreviations used: GPxs—glutathione peroxidases, GSH—glutathione, Nrf2—nuclear factor-erythroid-2-related factor 2, SODs—superoxide dismutases, VDR—vitamin D receptor.